Compare · GILD vs TECX
GILD vs TECX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Tectonic Therapeutic Inc. (TECX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and TECX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $166.72B, about 271.0x TECX ($615.1M).
- Over the past year, GILD is up 24.1% and TECX is up 48.9% - TECX leads by 24.8 points.
- GILD has been more active in the news (7 items in the past 4 weeks vs 2 for TECX).
- GILD has more recent analyst coverage (25 ratings vs 11 for TECX).
- Company
- Gilead Sciences Inc.
- Tectonic Therapeutic Inc.
- Price
- $134.23-1.50%
- $32.65+5.92%
- Market cap
- $166.72B
- $615.1M
- 1M return
- +5.49%
- +9.29%
- 1Y return
- +24.06%
- +48.88%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2018
- News (4w)
- 7
- 2
- Recent ratings
- 25
- 11
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Latest TECX
- Chief Scientific Officer Mcnamara Peter exercised 172 shares at a strike of $14.71 and sold $6,020 worth of shares (172 units at $35.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Reicin Alise covered exercise/tax liability with 924 shares, decreasing direct ownership by 0.30% to 310,623 units (SEC Form 4) to cover taxes
- SEC Form 4 filed by Chief Financial Officer Lochner Daniel
- Tectonic Therapeutic Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by Director Tipirneni Praveen P.
- SEC Form 4 filed by Director Donenberg Phillip B.
- SEC Form 4 filed by Director Springer Timothy A
- SEC Form 4 filed by Director Vitorovic Stefan
- SEC Form 4 filed by Director Chutter Jessica Caroline
- SEC Form 3 filed by new insider Chutter Jessica Caroline